Subtopic Deep Dive
Genetic Alterations in Childhood ALL
Research Guide
What is Genetic Alterations in Childhood ALL?
Genetic alterations in childhood acute lymphoblastic leukemia (ALL) refer to recurrent mutations, chromosomal translocations, and gene fusions such as IKZF1 deletions, Ph-like kinase lesions, and ETP-ALL mutations that drive leukemogenesis in pediatric patients.
Genomic profiling identifies key alterations like IKZF1 deletions (Mullighan et al., 2009, 1420 citations) and Ph-like ALL kinase-activating lesions (Roberts et al., 2014, 1347 citations). ETP-ALL features distinct somatic mutations revealed by whole-genome sequencing (Zhang et al., 2012, 1605 citations). JAK mutations occur in high-risk cases (Mullighan et al., 2009, 554 citations). Over 20 papers from the list detail these findings.
Why It Matters
IKZF1 deletions predict poor prognosis in B-ALL, guiding risk stratification (Mullighan et al., 2009). Ph-like ALL alterations enable tyrosine kinase inhibitor therapies, improving outcomes in relapsed cases (Roberts et al., 2014). ETP-ALL mutations inform aggressive subtype classification (Zhang et al., 2012). Survival improved from 1990-2005 due to genetic insights (Hunger et al., 2012). CRLF2 overexpression in B-ALL supports targeted diagnostics (Russell et al., 2009).
Key Research Challenges
Heterogeneity of Subtypes
Childhood ALL subtypes like Ph-like and ETP-ALL show diverse kinase-activating lesions and mutations (Roberts et al., 2014; Zhang et al., 2012). Profiling large cohorts remains resource-intensive. Standardizing subtype classification across studies is inconsistent.
Prognostic Prediction Accuracy
IKZF1 deletions associate with poor outcome, but co-occurring mutations complicate predictions (Mullighan et al., 2009). JAK mutations identify high-risk groups yet lack universal validation (Mullighan et al., 2009). Integrating multi-omics data for precise risk models is challenging.
Targeted Therapy Resistance
Ph-like lesions respond to TKIs, but resistance emerges from pathway redundancies (Roberts et al., 2014). ETP-ALL lacks effective targeted options despite known drivers (Zhang et al., 2012). Developing combinatorial therapies requires functional validation.
Essential Papers
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Christian Thiede, Christine Steudel, Brigitte Mohr et al. · 2002 · Blood · 1.7K citations
Constitutive activation of the FLT3 receptor tyrosine kinase, either by internal tandem duplication (ITD) of the juxtamembrane region or by point mutations in the second tyrosine kinase domain (TKD...
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Jinghui Zhang, Li Ding, Linda Holmfeldt et al. · 2012 · Nature · 1.6K citations
Early T-cell precursor acute lymphoblastic leukaemia (ETP ALL) is an aggressive malignancy of unknown genetic basis. We performed whole-genome sequencing of 12 ETP ALL cases and assessed the freque...
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
Charles G. Mullighan, Xiaoping Su, Jinghui Zhang et al. · 2009 · New England Journal of Medicine · 1.4K citations
Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL.
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner et al. · 2014 · New England Journal of Medicine · 1.3K citations
Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine k...
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T Terwilliger, Maher Abdul‐Hay · 2017 · Blood Cancer Journal · 1.2K citations
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
Stephen P. Hunger, Xiaomin Lu, Meenakshi Devidas et al. · 2012 · Journal of Clinical Oncology · 1.2K citations
Purpose To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute lymphoblastic leukemia (ALL) enrolled onto Ch...
Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study
Elisabet Bergsten, AnnaCarin Horne, Maurizio Aricò et al. · 2017 · Blood · 620 citations
Key Points Early introduction of cyclosporine did not improve HLH outcome in patients treated with the HLH-94 etoposide-dexamethasone backbone (P = .06). HLH-2004 may be improved by risk-group stra...
Reading Guide
Foundational Papers
Start with Mullighan et al. (2009) for IKZF1-prognosis link (1420 citations); Zhang et al. (2012) for ETP-ALL genetics (1605 citations); Roberts et al. (2014) for Ph-like lesions (1347 citations) to grasp core alterations.
Recent Advances
Terwilliger and Abdul-Hay (2017, 1228 citations) updates ALL genetics; Hunger et al. (2012, 1168 citations) links alterations to survival gains.
Core Methods
Whole-genome sequencing (Zhang et al., 2012); genomic profiling for deletions/fusions (Mullighan et al., 2009); kinase lesion identification (Roberts et al., 2014).
How PapersFlow Helps You Research Genetic Alterations in Childhood ALL
Discover & Search
Research Agent uses searchPapers and exaSearch to find papers on IKZF1 deletions, then citationGraph on Mullighan et al. (2009) reveals 1420 citing works including Ph-like extensions. findSimilarPapers expands to ETP-ALL genomics from Zhang et al. (2012).
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation frequencies from Roberts et al. (2014), verifies claims with CoVe against Hunger et al. (2012) survival data, and uses runPythonAnalysis for statistical comparison of prognosis across IKZF1-deleted vs. wild-type cohorts with GRADE scoring for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in Ph-like therapy resistance post-Roberts et al. (2014), flags contradictions between JAK mutation impacts (Mullighan et al., 2009), and uses latexEditText with latexSyncCitations for manuscript drafting. Writing Agent compiles diagrams via exportMermaid for fusion pathway graphs and latexCompile for publication-ready output.
Use Cases
"Run survival analysis on IKZF1 deletion cohorts from COG trials."
Research Agent → searchPapers('IKZF1 ALL') → Analysis Agent → readPaperContent(Mullighan 2009) → runPythonAnalysis(pandas survival curves from extracted data) → Kaplan-Meier plot output with p-values.
"Draft review section on Ph-like ALL genetics with citations."
Research Agent → citationGraph(Roberts 2014) → Synthesis Agent → gap detection → Writing Agent → latexEditText('Ph-like lesions review') → latexSyncCitations(10 papers) → latexCompile → PDF with figures.
"Find code for genomic profiling in childhood ALL papers."
Research Agent → searchPapers('childhood ALL genomics code') → Code Discovery → paperExtractUrls(Zhang 2012) → paperFindGithubRepo → githubRepoInspect → R/Bioconductor pipeline for variant calling.
Automated Workflows
Deep Research workflow scans 50+ ALL papers via searchPapers, structures report on alteration frequencies with CoVe verification. DeepScan applies 7-step analysis: search → readPaperContent(Mullighan 2009) → runPythonAnalysis(mutation stats) → GRADE → synthesis. Theorizer generates hypotheses on IKZF1-JAK co-mutations from Mullighan papers.
Frequently Asked Questions
What defines genetic alterations in childhood ALL?
Recurrent changes include IKZF1 deletions, Ph-like kinase fusions, ETP mutations, and JAK alterations driving leukemogenesis (Mullighan et al., 2009; Roberts et al., 2014; Zhang et al., 2012).
What methods identify these alterations?
Whole-genome sequencing detects ETP mutations (Zhang et al., 2012); genomic profiling reveals IKZF1 deletions and Ph-like lesions (Mullighan et al., 2009; Roberts et al., 2014).
What are key papers?
Mullighan et al. (2009, 1420 citations) on IKZF1; Roberts et al. (2014, 1347 citations) on Ph-like; Zhang et al. (2012, 1605 citations) on ETP-ALL.
What open problems exist?
Overcoming therapy resistance in Ph-like ALL; validating co-mutations for prognosis; developing targets for ETP-ALL (Roberts et al., 2014; Zhang et al., 2012).
Research Acute Lymphoblastic Leukemia research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Genetic Alterations in Childhood ALL with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers